Free Trial
→ Your Bank Account Is No Longer Safe (From Priority Gold) (Ad)
NASDAQ:MTSR

Metsera 5/12/2025 Earnings Report

Metsera logo
$26.97 -2.34 (-7.98%)
As of 12:32 PM Eastern
ProfileEarnings HistoryForecast

Metsera EPS Results

Actual EPS
-$1.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Metsera Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Metsera Announcement Details

Quarter
Date
5/12/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Metsera Earnings Headlines

Wells Fargo & Company Begins Coverage on Metsera (NASDAQ:MTSR)
June 22 at 1:13 AM | americanbankingnews.com
Wells Fargo Initiates Coverage of Metsera (MTSR) with Overweight Recommendation
June 20, 2025 | msn.com
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
June 25, 2025 | Priority Gold (Ad)
Promising Results Of Amylin Analogs In Obesity: Metsera Case Review
June 12, 2025 | seekingalpha.com
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results
June 11, 2025 | msn.com
Metsera extends gains after early-stage trial data for obesity therapy
June 10, 2025 | msn.com
See More Metsera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Metsera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metsera and other key companies, straight to your email.

About Metsera

Metsera (NASDAQ:MTSR), Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

View Metsera Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles